ironjustice
2011-05-14 22:57:44 UTC
Nicotine: Improves Cognitive Function
In a multicenter randomized controlled trial of 74 non-smoking
volunteers with mild cognitive impairment (MCI), the use of nicotine
treatment produced statistically significant improvement in paragraph
recall, delayed word recall accuracy, speed of memory, and choice
reaction time accuracy.
The six-month study, conducted by researchers at Duke University,
University of Vermont, Georgetown University, and Cognitive Drug
Research Ltd., with funding from the National Institute on Aging, also
showed a trend for a greater proportion of patients on nicotine to be
rated as improved compared to the placebo group.
Volunteers received either transdermal nicotine in doses that ranged
from 5-15 milligrams or placebo over a six-month period. Both groups
had similar adverse events rates and there were no effects secondary
to the nicotine. There were also no significant adverse effects for
nicotine other than a decrease in weight.
"Transdermal nicotine is a promising treatment for patients with early
cognitive deficits and warrants further studies, said Heidi K. White,
MD, of Duke University and lead author of the study. "It is safe,
effective, and tolerable and could improve quality of life for
patients with MCI and their families."
Source:
American Geriatrics Society
Who loves ya.
Tom
Jesus Was A Vegetarian!
http://tinyurl.com/2r2nkh
Man Is A Herbivore!
http://tinyurl.com/4rq595
DEAD PEOPLE WALKING
http://tinyurl.com/zk9fk
In a multicenter randomized controlled trial of 74 non-smoking
volunteers with mild cognitive impairment (MCI), the use of nicotine
treatment produced statistically significant improvement in paragraph
recall, delayed word recall accuracy, speed of memory, and choice
reaction time accuracy.
The six-month study, conducted by researchers at Duke University,
University of Vermont, Georgetown University, and Cognitive Drug
Research Ltd., with funding from the National Institute on Aging, also
showed a trend for a greater proportion of patients on nicotine to be
rated as improved compared to the placebo group.
Volunteers received either transdermal nicotine in doses that ranged
from 5-15 milligrams or placebo over a six-month period. Both groups
had similar adverse events rates and there were no effects secondary
to the nicotine. There were also no significant adverse effects for
nicotine other than a decrease in weight.
"Transdermal nicotine is a promising treatment for patients with early
cognitive deficits and warrants further studies, said Heidi K. White,
MD, of Duke University and lead author of the study. "It is safe,
effective, and tolerable and could improve quality of life for
patients with MCI and their families."
Source:
American Geriatrics Society
Who loves ya.
Tom
Jesus Was A Vegetarian!
http://tinyurl.com/2r2nkh
Man Is A Herbivore!
http://tinyurl.com/4rq595
DEAD PEOPLE WALKING
http://tinyurl.com/zk9fk